Though the new 33 CMT cohort had mixed grades and unknown ER/PR status, all cases within our previous cohort of 27 CMTs were higher grade ERneg cancer so that SFRP1 suppression is likely to have an additional role to possibly enhancing ER-signalling in our new cohort. The gene discussed is SFRP1; the disease is cancer.